Moderna Therapeutics is a biotech company that develops and sells vaccines for diseases. Its recent announcements show that it has procured nearly $4.7 billion in revenue for fiscal year 2020 and that its sales are expected to be up 9% year-over-year. The company attributed this increase in revenue to higher product sales, especially for its COVID vaccine.
Moderna stock currently has a Composite Rating of 48, which is an indicator of the strength of its fundamentals and technicals. Its stock price was 23 when it went public in late 2018 and has risen nearly threefold since then. That’s a stellar performance, but it may not be enough to sustain investors’ interest in the stock at this time.
There are several other metrics investors should be aware of, including the company’s annual dividend rate and yield. The dividend rate is the percentage of profit that the company pays to its shareholders each year. Dividend yield is the total dividends paid divided by the closing price. You can also view the sector or SIC code of the company, which will give you a better idea of the company’s prospects.
The overall industry PEG ratio of the Medical – Biomedical and Genetics sector is 1.39. This puts this industry in the top 25 percent of all 250+ industries. As a result, it is a good option for investors seeking to make money in this sector. You can also invest in the company’s stock by evaluating its growth potential and the company’s earnings outlook.
Moderna has a $48 billion market cap and delivers the highly effective COVID vaccine. It also has a pipeline of vaccines and therapeutics that are advancing. Moderna currently trades at 2.6X cash and has a huge share buyback program underway. As a result, Moderna’s stock is a bargain at this price.
